Cerus to Present at the Morgan Stanley Global Healthcare Conference on September 14, 2016

Cerus Corporation (NASDAQ:CERS) announced today that William “Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Morgan Stanley Healthcare Conference at 1:00PM ET on Wednesday, September 14, 2016.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160907005001/en/